DaVita Shares Fall Sharply as Dialysis Reform Proposal Surfaces

Market reports say shares of kidney care provider DaVita fell sharply, with one report putting the decline at about 6% as a proposed kidney care plan drew attention. Several outlets note the drop came as the Department of Health and Human Services sought reforms in the dialysis market, and one report adds that peer Fresenius also declined. Another report observed that the stock underperformed compared with competitors that day. A separate report noted the company has scheduled an investor conference call for its third quarter 2026 results.

DaVita operates dialysis centers and provides kidney care services, so its business is closely tied to how dialysis treatment is organized and paid for in the United States. Proposed changes to the market can affect how investors view the company's operating environment, which helps explain why the stock moved on the news.

What our numbers show: the last close was $175.35 on 20 October 2026, a move of -6.23% on that trading day. The X-Ray Score is 66 out of 100, and the fair value label from the site's models is Undervalued, which is the output of those models rather than advice.

Headlines change quickly, so the company's own announcements and SEC filings remain the primary source for details.